It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- Founded in 2000 and based in Israel, Mediwound is a commercial stage biotech focused on developing, manufacturing, and commercializing biotherapeutic solutions for tissue repair and regeneration, specifically for severe burn and wound management
- Lead asset NexoBrid is approved in the EU and has a PDUFA in the US 6/29/21
- Treatment of severe burns
- Mediwound has 2 other assets. Click here for an overview of their pipeline